U.S., June 28 -- ClinicalTrials.gov registry received information related to the study (NCT07041983) titled '24-h Energy Expenditure and Anti-obesity Medication' on May 28.
Brief Summary: This study investigates the long-term effects of anti-obesity medications (Semaglutide and Tirzepatide) on energy metabolism (24-hour energy expenditure and substrate oxidation) and body composition via Dual-energy X-ray absorptiometry (DXA)
Study Start Date: July 01
Study Type: OBSERVATIONAL
Condition:
Obesity
Intervention:
DRUG: anti obesity medication
Patients with obesity or overweight, with at least one weight-related comorbidity who are expected to start treatment with Semaglutide (Wegovy) or Terzepatide (Mounjaro) at enrolment will be eligib...